Overview
- UnitedHealth raised its Q4 2025 dividend by 5.2% year over year, signaling renewed confidence.
- Management characterizes 2026 as a transition year to reset operations and position for a rebound beginning in 2027.
- Analyst consensus projects about a 41% EPS decline for 2025 followed by roughly 14.1% annual EPS growth over the next five years.
- Coverage notes recovering profits and improving stability after two difficult years that included a major cyberattack and leadership turnover.
- Analysts cite the company’s scale and diversification as recovery drivers but warn of regulatory and execution risks, with one author outlining $400, $450, and $500 share-price targets over one to three years.